JACQUES JM
VAN DONGEN
Investigador
KU Leuven
Lovaina, BélgicaPublicaciones en colaboración con investigadores/as de KU Leuven (16)
2023
-
Plasma cells are not restricted to the CD27+ phenotype: characterization of CD27-CD43+ antibody-secreting cells
Frontiers in Immunology, Vol. 14
2022
-
Critical Implications of IVDR for Innovation in Diagnostics: Input from the BioMed Alliance Diagnostics Task Force
HemaSphere, Vol. 6, Núm. 6, pp. E724
2015
-
Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds
Cytometry Part A, Vol. 87, Núm. 2, pp. 145-156
2012
-
Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia
Leukemia, Vol. 26, Núm. 9, pp. 1976-1985
2010
-
Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay
Best Practice and Research: Clinical Haematology, Vol. 23, Núm. 3, pp. 333-345
2009
-
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients
Leukemia, Vol. 23, Núm. 6, pp. 1106-1117
2005
2004
-
An inv(16)(p13q22) positive acute myeloid leukaemia relapsing as acute precursor B-cell lymphoblastic leukaemia.
Haematologica, Vol. 89, Núm. 8
-
Detection of minimal residual disease in acute leukemia
Journal of Biological Regulators and Homeostatic Agents, Vol. 18, Núm. 2, pp. 146-154
-
Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease - A study within the Europe against cancer program [9]
Leukemia
-
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin |(Mylotarg®) treatment in acute myeloid leukemia patients
Leukemia, Vol. 18, Núm. 5, pp. 983-988
2003
2002
-
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
Leukemia, Vol. 16, Núm. 9, pp. 1627-1636
-
Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia
Leukemia, Vol. 16, Núm. 3, pp. 368-375